GSK has reported positive Phase III results from its AReSVi-006 trial for Arexvy, an RSV vaccine for adults. The study demonstrated a single dose's efficacy at 62.9% against RSV-related lower respiratory tract disease (LRTD) and 67.4% against severe cases over three RSV seasons in adults aged 60 and older. The FDA [...] The post Positive Phase III Trial Results for GSK’s Arexvy Vaccine in Older Adults Lead to FDA Approval appeared first on HealthEconomics.com ..read more

A new CAR T cell therapy using donor-derived, CRISPR-modified immune cells has successfully treated three people with severe autoimmune diseases in China. This method uses cells from a single donor instead of a patient's own cells, which could make treatments more affordable and accessible by enabling mass production. The trial showed [...] The post Breakthrough in CAR T Cell Therapy Using Donor-Derived Cells for Autoimmune Diseases appeared first on HealthEconomics.com ..read more

A Congressional Budget Office report estimates that expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, starting in 2026, with 12.5 million beneficiaries qualifying. Initial drug costs would rise from $1.6 billion in 2026 to $7.1 billion by 2034, with minimal health-related savings. Two-thirds of Medicare [...] The post Medicare Expansion for Weight Loss Drugs Estimated at $35 Billion appeared first on HealthEconomics.com ..read more

Flatiron Health and Lifebit have expanded their partnership to Japan with the goal of enhancing cancer research through the secure use of real-world data (RWD). Flatiron, known for its work in oncology, and Lifebit, which provides AI-driven research tools, will use Lifebit's Trusted Research Environment (TRE) to facilitate secure analysis of [...] The post Flatiron Health and Lifebit Extend Partnership to Advance Cancer Research in Japan Using Secure Real-World Data appeared first on HealthEconomics.com ..read more

GBI Biomanufacturing and Allterum Therapeutics have announced a strategic manufacturing partnership for the production of Allterum's therapeutic antibody 4A10 for clinical trials. 4A10, a monoclonal antibody targeting CD127, will be tested in Phase 1/2a clinical trials that focus on patients with acute lymphoblastic leukemia (ALL), with future trials expanding to other [...] The post GBI Biomanufacturing and Allterum Therapeutics Partner to Advance Antibody Therapy for Cancer Clinical Trials appeared first on HealthEconomics.com ..read more

Enovo Life Sciences, co-founded by life sciences veterans Mario Philips and Roel Gordijn, has launched in collaboration with global investor Warburg Pincus. Enovo aims to acquire companies to establish a leading life sciences platform focusing on biologics and advanced therapies. Backed by Warburg Pincus's $17.3 billion fund, Enovo will leverage Philips [...] The post Enovo Life Sciences Launches Biologics and Advanced Therapies Platform with Warburg Pincus appeared first on HealthEconomics.com ..read more

A significant Marburg virus outbreak in Rwanda, with 27 cases and nine deaths, is raising global concerns. The World Health Organization (WHO) has classified the risk of regional spread as high, while global risk remains low. Most cases have occurred among healthcare workers in Kigali, a major travel hub. The virus, [...] The post Global Concern Possible Over Rwanda’s Marburg Outbreak appeared first on HealthEconomics.com ..read more

UnitedHealth is suing the Centers for Medicare & Medicaid Services (CMS) over reduced star ratings for its Medicare Advantage (MA) plans, following similar successful lawsuits by Elevance and Scan Health Plan. These legal actions arise from CMS's adjustments to star rating calculations, which impacted insurers' scores. UnitedHealth's case focuses on a [...] The post UnitedHealth Challenges CMS Over Medicare Advantage Star Ratings appeared first on HealthEconomics.com ..read more

A recent report from Deloitte's Center for Health Solutions examines the economic implications of health equity in the United States, estimating that achieving health equity could unlock over $1 trillion in annual economic gains. A breakdown of the findings are below. Health Disparities: Approximately 30% of the U.S. population experiences health [...] The post Unlocking Over $1 Trillion in Economic Gains? The Economic Case for Health Equity in the U.S. appeared first on HealthEconomics.com ..read more

The U.S. Food and Drug Administration (FDA) announced that Eli Lilly’s weight-loss drug tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight management, is no longer in shortage. The drug had been listed as "in short supply" due to overwhelming demand. The shortage's resolution is expected to stabilize availability, although [...] The post FDA Announces Eli Lilly’s Mounjaro and Zepbound Are No Longer in Shortage appeared first on HealthEconomics.com ..read more